Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio.Non-invasive Liquid Biopsy Technology Shapes the Precision Diagnostics Landscape
Advances in next-generation sequencing-based companion diagnostics (CDx) and liquid biopsy (LBx) enable precision medicine approaches toward diseases such as cancer. Another aspect changing the diagnostics industry is linking automation to digital technologies to improve efficiency and productivity. This includes leveraging artificial intelligence to enhance workflow and accuracy.
This analysis shows that the top 5 companies in the US liquid biopsy market - Exact Sciences, Guardant Health, Roche/Foundation Medicine, Natera, and LabCorp - account for 77.5% of its revenue in 2020. The analyst expects the market to reach $7.02 billion by 2025 at a 14% CAGR.
The report provides updates on the competitive landscape by analyzing market dynamics, participants, and investments. It also offers stakeholders insights through forecasts, analysis by therapy (oncology and non-oncology) and product type (kits and reagents, instruments and analysis platforms, testing and development services), and growth opportunities.
Table of Contents
1. Strategic Imperatives
2. Growth Opportunity Analysis - Liquid Biopsy
3. Growth Opportunity Analysis - Oncology (Therapy Segment)
4. Growth Opportunity Analysis - Non-oncology (Therapy Segment)
5. Competitive Landscape Analysis
6. Growth Opportunity Universe
7. Next Steps
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Exact Sciences
- Guardant Health
- LabCorp
- Natera
- Roche/Foundation Medicine
